FDA Brief

Warning letters Drugs

FDA warning letter to

Choice All Natural, Inc. dba Om Botanical

High riskIssued Oct 21, 2024Posted Oct 29, 2024Center for Drug Evaluation and Research (CDER)

FDA warns Om Botanical of Apex, NC over filthy manufacturing, an unapproved rash cream, and lapsed FDA registration.

What happened

FDA inspected Choice All Natural, Inc. dba Om Botanical at 1019 Classic Road, Apex, NC, from January 17 to February 26, 2024. Investigators saw pest activity in raw material storage, water leaks and missing ceiling tiles in the manufacturing area, and a quality control lab used for meal preparation, dishwashing and storing soiled clothing. FDA also told the firm on August 22, 2024 that a sample of its Rash & Itch drug product collected during the inspection had tested positive, and asked for an investigation into batches potentially contaminated with Candida parapsilosis.

What FDA found

  1. The buildings were not kept clean and free of pests: investigators saw pest activity where raw materials are stored, water leaks and missing ceiling tiles in the manufacturing area, and a quality control lab used for preparing meals and storing dirty clothes.

    21 CFR 211.56(a)
  2. The firm released batches without testing each active ingredient's identity and strength, and without testing for objectionable microorganisms.

    21 CFR 211.165(a) and 211.165(b)
  3. Expiration dates on the products were not supported by any ongoing stability testing program.

    21 CFR 211.137(a)
  4. Om Botanical Rash & Itch Cream is an unapproved new drug because its combination of zinc oxide, witch hazel and colloidal oatmeal is not allowed under the over-the-counter skin protectant monograph, and it has no FDA-approved application.

    FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)
  5. Because the Rash & Itch Cream does not meet the requirements for marketing without an approved application, it is misbranded.

    FD&C Act section 502(ee), 21 U.S.C. 352(ee)
  6. The firm's FDA establishment registration expired on December 31, 2021 while it kept making and shipping drugs, and its products are not listed with FDA, which makes them misbranded.

    FD&C Act sections 510 and 301(p), 21 U.S.C. 360 and 331(p); 21 CFR Part 207

What FDA wants

FDA tells the firm to correct the violations promptly and to reply in writing within 15 working days with its corrective action plans, risk assessments for products already distributed, and an investigation into batches possibly contaminated with Candida parapsilosis. FDA also recommends hiring a qualified CGMP consultant to audit the whole operation.

Who should pay attention

  • retailers and distributors selling Om Botanical drug products
  • brands that buy OTC topical products from this contract manufacturer
  • companies that let their FDA drug registration or listing lapse

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. CNC Noodle Corporation

    FDA warned CNC Noodle Corporation that its Hayward, California noodle plant had insanitary conditions, no pathogen or allergen controls, and mislabeled products.

    High risk
  2. USV Private Limited

    FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

    High risk
  3. Next Medical Products Company, LLC

    FDA warns Next Medical Products that its ultrasound gels were contaminated and made without required quality controls or clearance.

    High risk
  4. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk